Dacarbazine Production Cost Reports

The report provides a detailed analysis essential for establishing a Dacarbazine manufacturing plant. It encompasses all critical aspects necessary for Dacarbazine production, including the cost of Dacarbazine production, Dacarbazine plant cost, Dacarbazine production costs, and the overall Dacarbazine manufacturing plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Dacarbazine production plant. These encompass manufacturing processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Dacarbazine is a chemotherapy medication used to treat malignant melanoma and Hodgkin's lymphoma. It works by restricting the DNA of cancer cells and preventing them from growing and dividing, ultimately leading to their death. This is given via an intravenous infusion as either a slow injection or over 24 hours. It is a cytotoxic chemotherapeutic agent with activity and use in Hodgkin's lymphoma and has been commonly administered in combination chemotherapy regimens for this disease (in second-line therapy). It is indicated for advanced soft tissue sarcomas other than Kaposi & mesothelioma. It is photosensitive, and thus, reconstituted solutions should be shielded during administration. Its usage requires treatment plans that minimize risks and maximize benefits for patients.

The market for Dacarbazine is driven mainly by its use as an effective treatment for several cancers. Its use in treating malignant melanoma and Hodgkin's lymphoma contributes to its growing demand. The advanced cancer treatment protocols coupled with research and clinical trials improve its role in oncology. Also, regulatory approvals for new and better formulations, as well as delivery methods, contribute to its application and accessibility. Also, better financing for oncology research and drug development makes it a product of interest. Thus, industrial dacarbazine procurement is influenced by its usage in treating malignant melanoma and Hodgkin's lymphoma, along with advanced treatment protocols, approvals for new formulations, investment in oncology research, and expansion of healthcare infrastructure in emerging markets.

Raw Material for Dacarbazine Production

According to the Dacarbazine manufacturing plant project report, the key raw materials used in the production of Dacarbazine include (5-Aminoimidazole-4-carboxamide)-Dimethylamine- Nitrous acid-(1,1'-Carbonyldiimidazole).

Manufacturing Process of Dacarbazine

The extensive Dacarbazine production cost report consists of the following major industrial manufacturing process:

1. From 5-Aminoimidazole-4-carboxamide, Dimethylamine, Nitrous acid, and 1,1'-Carbonyldiimidazole: The industrial manufacturing process for Dacarbazine involves several steps. First, 5-aminoimidazole-4-carboxamide is reacted with dimethylamine, forming an intermediate compound. This intermediate is treated with nitrous acid that forms DMI after reduction. After this, DMI is reacted with 1,1'-carbonyldiimidazole, forming Dacarbazine. Finally, Dacarbazine is purified and formulated as per requirement.

Dacarbazine is a white microcrystalline solid. Its molecular formula is CHNO, and it has a molar mass of 182.19 g/mol. It is faintly soluble in water and has a melting point of around 255°C. It is sensitive to light and heat and stored at a temperature below 10°C. It decomposes into 4-diazoimidazole-5-carboxamide in the presence of light and decomposes explosively at temperatures above 250°C. Its reconstituted solution's stability is up to 48 hours. It is incompatible with heparin and hydrocortisone. All these physical and chemical properties contribute to its pharmaceutical applications.